JP2005538701A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538701A5
JP2005538701A5 JP2004502947A JP2004502947A JP2005538701A5 JP 2005538701 A5 JP2005538701 A5 JP 2005538701A5 JP 2004502947 A JP2004502947 A JP 2004502947A JP 2004502947 A JP2004502947 A JP 2004502947A JP 2005538701 A5 JP2005538701 A5 JP 2005538701A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004502947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538701A (ja
JP4557714B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/015044 external-priority patent/WO2003094859A2/en
Publication of JP2005538701A publication Critical patent/JP2005538701A/ja
Publication of JP2005538701A5 publication Critical patent/JP2005538701A5/ja
Application granted granted Critical
Publication of JP4557714B2 publication Critical patent/JP4557714B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004502947A 2002-05-10 2003-05-12 ＥｐｈＡ２モノクローナル抗体およびその使用法 Expired - Fee Related JP4557714B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37932202P 2002-05-10 2002-05-10
US41821302P 2002-10-14 2002-10-14
US46050703P 2003-04-03 2003-04-03
PCT/US2003/015044 WO2003094859A2 (en) 2002-05-10 2003-05-12 Epha2 monoclonal antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010115398A Division JP2010246546A (ja) 2002-05-10 2010-05-19 ＥｐｈＡ２モノクローナル抗体およびその使用法

Publications (3)

Publication Number Publication Date
JP2005538701A JP2005538701A (ja) 2005-12-22
JP2005538701A5 true JP2005538701A5 (enExample) 2008-07-03
JP4557714B2 JP4557714B2 (ja) 2010-10-06

Family

ID=29424523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004502947A Expired - Fee Related JP4557714B2 (ja) 2002-05-10 2003-05-12 ＥｐｈＡ２モノクローナル抗体およびその使用法
JP2010115398A Pending JP2010246546A (ja) 2002-05-10 2010-05-19 ＥｐｈＡ２モノクローナル抗体およびその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010115398A Pending JP2010246546A (ja) 2002-05-10 2010-05-19 ＥｐｈＡ２モノクローナル抗体およびその使用法

Country Status (8)

Country Link
US (3) US20040028685A1 (enExample)
EP (1) EP1519956B1 (enExample)
JP (2) JP4557714B2 (enExample)
AT (1) ATE525398T1 (enExample)
AU (2) AU2003243228B2 (enExample)
CA (1) CA2485373A1 (enExample)
ES (1) ES2373715T3 (enExample)
WO (1) WO2003094859A2 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
JP4557714B2 (ja) * 2002-05-10 2010-10-06 メディミューン，エルエルシー ＥｐｈＡ２モノクローナル抗体およびその使用法
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
AU2003239585B2 (en) * 2002-05-23 2009-06-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (LMW-PTP) as diagnostic and therapeutic target
JP4762889B2 (ja) 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
EP1618184A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
EP1628992A4 (en) * 2003-05-13 2008-04-16 Novartis Vaccines & Diagnostic METHOD FOR MODULATING THE METASTASIS AND METASTASES OF RELATED EVENTS IN THE SKELETON
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
US7604799B2 (en) 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
CA2531069A1 (en) * 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
US20050042664A1 (en) * 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
JP4860477B2 (ja) * 2003-11-20 2012-01-25 メディミューン，エルエルシー ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
EP1732580A4 (en) * 2003-12-24 2008-01-23 Medimmune Inc EPHA2 VACCINES
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
EP2287194B1 (en) 2004-03-12 2016-10-26 Vasgene Therapeutics, Inc. Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
DE602005025459D1 (de) 2004-03-12 2011-02-03 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) * 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
CA2562771C (en) 2004-04-12 2013-04-09 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
US20060019342A1 (en) * 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
CA2577370A1 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
AU2005299767A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
CA2585703A1 (en) * 2004-10-27 2006-05-04 Medimmune Inc. Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
AU2005299353A1 (en) * 2004-10-27 2006-05-04 Medimmune, Llc Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
WO2006084226A2 (en) * 2005-02-04 2006-08-10 Raven Biotechnologies, Inc. Antibodies that bind to epha2 and methods of use thereof
JP2008536874A (ja) * 2005-04-15 2008-09-11 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 中性脂質組成物によるｓｉＲＮＡの送達
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
CN101228181B (zh) * 2005-07-20 2013-09-18 默沙东公司 Hcv ns3蛋白酶抑制剂
KR20080080482A (ko) * 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
US20090220527A1 (en) * 2005-12-21 2009-09-03 Medlmmune, Llc Affinity optimized epha2 agonistic antibodies and methods of use thereof
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
JP2010530437A (ja) * 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
DK2173378T3 (da) 2007-06-27 2014-05-12 Admune Therapeutics Llc Komplekser af il-15 og il-15ralfa og anvendelser deraf
CA2696164C (en) 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
DK2199390T3 (en) * 2007-08-30 2017-04-03 Daiichi Sankyo Co Ltd ANTI-EphA2 ANTIBODY
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012012759A2 (en) 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
EP2686020B1 (en) 2011-03-17 2017-02-22 The University of Birmingham Re-directed immunotherapy
AU2012216627A1 (en) * 2011-11-14 2013-05-30 Newcastle Innovation Ltd. Composition and methods for the diagnosis, prognosis and treatment of leukemia
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SG10201913324PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3572426A4 (en) * 2017-01-23 2020-12-23 Toyo University ANTI-BODY ANTI-EPHA2 AND IMMUNOLOGICAL DETECTION OF EPHA2 CALLING ANTI-BODY AUDIT
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
US20210017284A1 (en) * 2018-03-19 2021-01-21 Abeome Corporation High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
EP3773718A4 (en) 2018-04-06 2022-01-19 aTyr Pharma, Inc. COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES
US11702482B2 (en) 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
EP4031576A1 (en) 2019-09-18 2022-07-27 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
EP4037711A4 (en) * 2019-10-03 2024-02-14 Atyr Pharma, Inc. COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES
CN115279403A (zh) 2020-02-21 2022-11-01 宏观基因有限公司 Cd137结合分子及其用途
WO2022133092A1 (en) 2020-12-16 2022-06-23 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
WO2022187710A1 (en) 2021-03-05 2022-09-09 Atreca, Inc. Epha2 antibodies
US20250340655A1 (en) * 2022-05-27 2025-11-06 Taipei Medical University Epha2-targeting antibodies and their applications in cancer treatment
CN116693597B (zh) * 2023-03-09 2024-06-21 南京大学 一种对苯酚衍生物、多肽和蛋白质中酪氨酸进行硝基化的方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31252A (en) * 1861-01-29 Improvement in iron ties for cotton-bales
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU663727B2 (en) * 1991-08-22 1995-10-19 Becton Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
WO1993011794A1 (en) * 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837448A (en) * 1992-05-15 1998-11-17 The Salk Institute For Biological Studies Protein-tyrosine kinase genes
PT669929E (pt) * 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
WO1994011020A1 (en) * 1992-11-13 1994-05-26 Amgen Inc. Eck receptor ligands
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5814479A (en) * 1994-01-04 1998-09-29 Zhou; Renping Bsk receptor-like tyrosine kinase
WO1995028484A1 (en) * 1994-04-15 1995-10-26 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5795734A (en) * 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5876949A (en) * 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5795775A (en) * 1996-09-26 1998-08-18 Becton Dickinson And Company Culture vessel and assembly
US5761934A (en) * 1996-10-22 1998-06-09 Kuo; Li-Tsao Cable lock and an universal hold-down support
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
WO1999008696A1 (en) * 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EP1135153B1 (en) * 1998-11-20 2005-04-27 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
ES2357296T3 (es) * 1999-08-17 2011-04-25 Purdue Research Foundation Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer.
PT1242060E (pt) * 1999-08-17 2006-08-31 Glaxo Group Ltd Tratamento da doenca metastatica
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU4139801A (en) * 1999-12-06 2001-06-12 Board Of Trustees Of The University Of Arkansas, The Controlled delivery of antigens
JP4992068B2 (ja) * 2000-01-27 2012-08-08 メディミューン，エルエルシー 超高親和性中和抗体
AU4002001A (en) * 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
AU5697001A (en) * 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
ES2649037T3 (es) * 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
AU2002316251A1 (en) * 2001-06-18 2003-01-02 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US7135334B2 (en) * 2001-06-20 2006-11-14 Genentech, Inc. PRO20044 nucleic acids
JP2003059182A (ja) * 2001-08-10 2003-02-28 Teac Corp １ビット形式ディジタル信号の記録方法及び記録装置及び付加装置
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
JP4557714B2 (ja) * 2002-05-10 2010-10-06 メディミューン，エルエルシー ＥｐｈＡ２モノクローナル抗体およびその使用法
WO2004010935A2 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US7504211B2 (en) * 2002-08-27 2009-03-17 Bristol-Myers Squibb Company Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
AU2003268345A1 (en) * 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2005538701A5 (enExample)
JP2006507013A5 (enExample)
RU2421465C2 (ru) Антитела к рецептору igf-i
US9249223B2 (en) Humanized anti CXCR4 antibodies for the treatment of cancer
JPWO2019173420A5 (enExample)
JP2011157397A5 (enExample)
JP2008529497A5 (enExample)
JP2007504280A5 (enExample)
CN109970856A (zh) 抗lag-3抗体及其用途
JP2008529494A5 (enExample)
JP2017538439A5 (enExample)
TW200918556A (en) Treatment of tumors using specific anti-L1 antibody
KR20140027051A (ko) 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
CN112166125A (zh) 全人源的抗lag-3抗体及其应用
CN109414489B (zh) 网蛋白-1结合抗体及其用途
US20220154296A1 (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
JP2009544574A5 (enExample)
CN110386981A (zh) 抗gitr抗体及其用途
AU2020371040B2 (en) Means and methods for treating subjects with HER2 and HER3 positive cancer
JP2007516226A5 (enExample)
AU2017277288B2 (en) Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer
RU2825845C2 (ru) Применение антитела против pd-1 в изготовлении лекарственного средства для лечения солидных опухолей
CN121008043A (zh) Axl-gas6复合物的检测方法及在心肌梗死患者中的应用
JP2025533015A (ja) 薬物抵抗性肝細胞癌の処置
JPWO2022013775A5 (enExample)